Get the Stockscreener App
4.43
3.12%
0.11
Genprex Inc stock is traded at $4.43, with a volume of 230.79K.
It is up +3.12% in the last 24 hours and down -41.92% over the past month.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
See More
Previous Close:
$4.32
Open:
$4.2
24h Volume:
230.79K
Relative Volume:
0.84
Market Cap:
$2.27M
Revenue:
-
Net Income/Loss:
$-16.73M
P/E Ratio:
-0.0132
EPS:
-335.7162
Net Cash Flow:
$-14.29M
1W Performance:
+6.32%
1M Performance:
-41.92%
6M Performance:
+147.50%
1Y Performance:
-58.01%
1-Day Range:
$4.06
$4.8921
1-Week Range:
$4.06
$5.2373
52-Week Range:
$0.4229
$55.00
Genprex Inc Stock (GNPX) Company Profile
Name
Genprex Inc
Sector
Industry
Phone
512-537-7997
Address
1601 TRINITY STREET, BLDG. B, AUSTIN, TX
Compare GNPX vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GNPX
Genprex Inc
|
4.49 | 2.18M | 0 | -16.73M | -14.29M | -335.72 |
VRTX
Vertex Pharmaceuticals Inc
|
515.76 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.65 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.87 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
211.83 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.63 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Genprex Inc Stock (GNPX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-21 | Initiated | National Securities | Buy |
| Apr-29-19 | Initiated | Noble Capital Markets | Outperform |
Genprex Inc Stock (GNPX) Latest News
Genprex, Inc. Q2 2026: Net loss $(4.45M), EPS $(9.40) — 10-Q Summary - TradingView
Genprex (NASDAQ: GNPX) details Q2 loss and cash runway into 2027 - Stock Titan
GNPX|Genprex Inc|Price:4.320|Chg%:-0.550 - TradingKey
Genprex Inc (STU:2DE1) Stock Earnings Transcripts - GuruFocus
Genprex Inc (STU:2DE1) Stock Price & 30 Year Financial Data - GuruFocus
Genprex Inc (GNPX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Genprex Inc (GNPX) Stock News Today - TradingKey
Genprex Regains Nasdaq Compliance, Listing Status Secured - The Globe and Mail
Genprex, Inc. (NASDAQ: GNPX) regains Nasdaq minimum bid compliance - Stock Titan
Genprex partners with Roche Diagnostics on biomarker validation for NSCLC - Yahoo Finance
Genprex, Roche Partner on NSCLC Biomarker Validation - TipRanks
Genprex Shares Rise After Collaboration With Roche Diagnostics - finance.yahoo.com
GNPX Stock Draws Trader Focus After Wild Price Swing - StocksToTrade
Why is Genprex stock sliding today? By Investing.com - Investing.com Canada
Weekly Recap: Nasdaq exception and Roche Diagnostics TROP2 validation - TradingView
Genprex stock rises on Roche Diagnostics collaboration By Investing.com - Investing.com India
Genprex partners with Roche on lung cancer biomarker studies - Investing.com Nigeria
Genprex partners with Roche on lung cancer biomarker studies By Investing.com - Investing.com Canada
Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies - marketscreener.com
Genprex Granted Nasdaq Listing Exception Amid Compliance Push - The Globe and Mail
Genprex Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Nasdaq panel grants Genprex (NASDAQ: GNPX) conditional listing reprieve - Stock Titan
Genprex Inc (GNPX) Institutional Confidence - TradingKey
Genprex Inc (GNPX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Genprex Inc (GNPX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
GNPX|Genprex Inc|Price:7.735|Chg%:-0.075 - TradingKey
GNPX|Genprex Inc|Price:4.700|Chg%:+0.230 - TradingKey
Genprex Inc Revenue Breakdown – LSE:0A8I - TradingView
AMD Stock Price Today, Analysis, News and Trading Ideas - Stocktwits
Gross margin % of Genprex Inc – MUN:2DE1 - TradingView
CapEx per share of Genprex Inc – MUN:2DE1 - TradingView
Dilution adjustment of Genprex Inc – MUN:2DE1 - TradingView
Total debt of Genprex Inc – MUN:2DE1 - TradingView
Total revenue of Genprex Inc – MUN:2DE1 - TradingView
Genprex (GNPX) Virtual Road Show with CEO Rodney Varner Transcript - GuruFocus
Genprex Inc C-Suite Interview with Noble Capital Markets Transcript - GuruFocus
Genprex (GNPX) Channelchek C-Suite Series, CEO Rodney Varner interview with Noble's Dr. Ahu Demir Transcript - GuruFocus
Genprex Inc Global One Media Interview Transcript - GuruFocus
Genprex Inc at H C Wainwright Global Investment Conference (Virtual) Transcript - GuruFocus
Cash flow from financing activities of Genprex Inc – FWB:2DE1 - TradingView
Net income of Genprex Inc – MUN:2DE1 - TradingView
Genprex Inc (FRA:2DE1) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Genprex Inc (FRA:2DE1) Stock Earnings Transcripts - GuruFocus
Net income of Genprex Inc – FWB:2DE1 - TradingView
Genprex Inc (STU:2DE1) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Genprex (GNPX) Q1 2026 Earnings: Pre-Revenue Biotech Reports Net Loss of -$0.64 Per ShareEarnings Call Q&A - dars.gov.et
Genprex Announces Reverse Stock Split Amid Nasdaq Compliance Push - The Globe and Mail
Genprex Inc. (GNPX) Edges Higher Amid Controlled Trading: Key Levels to WatchgetLinesFromResByArray error: size == 0 - dars.gov.et
Stock Splits Calendar for: - Yahoo! Finance Canada
Genprex Inc. (GNPX) Slides 5% as Biotech Stock Tests Key SupportFibonacci Arc - dars.gov.et
Genprex Inc Stock (GNPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Genprex Inc Stock (GNPX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| LONGNECKER BRENT M | Director |
Apr 14 '26 |
Sale |
1.23 |
8 |
10 |
9,157 |
3.00%
1.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):